The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Roberts Christopher D. since 2020.
This trader's CIK number is 1788368.
At the time of last reporting, Roberts Christopher D. was the Chief Scientific Officer of Black Diamond Therapeutics, Inc.. (stock ticker symbol BDTX).
Also see all insider trading activities at Black Diamond Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2021 | BDTX | 0 | $0 | 10,000 | $271,601 | 10,000 | $108,600 |
2020 | BDTX | 0 | $0 | 15,000 | $487,643 | 18,200 | $197,652 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2021-04-05 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2021-04-05 | BDTX | Sale | 2,500 | 25.54 | 63,847 |
2021-03-03 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2021-03-03 | BDTX | Sale | 2,500 | 26.21 | 65,522 |
2021-02-03 | BDTX | Sale | 2,500 | 25.35 | 63,375 |
2021-02-03 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2021-01-04 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2021-01-04 | BDTX | Sale | 2,500 | 31.54 | 78,857 |
2020-12-15 | BDTX | Option Ex | 3,200 | 10.86 | 34,752 |
2020-12-03 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2020-12-03 | BDTX | Sale | 2,500 | 32.42 | 81,054 |
2020-11-11 | BDTX | Option Ex | 5,000 | 10.86 | 54,300 |
2020-11-11 | BDTX | Sale | 5,000 | 34.90 | 174,500 |
2020-11-03 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2020-11-03 | BDTX | Sale | 2,500 | 31.95 | 79,872 |
2020-10-05 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2020-10-05 | BDTX | Sale | 2,500 | 31.59 | 78,987 |
2020-09-03 | BDTX | Option Ex | 2,500 | 10.86 | 27,150 |
2020-09-03 | BDTX | Sale | 2,500 | 29.29 | 73,230 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Roberts Christopher D. (Chief Scientific Officer of Black Diamond Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.